Michael Zalutsky, Ph.D

Co-Founder

Michael R. Zalutsky, Ph.D., is the Jonathan Spicehandler, M.D., Professor of Neuro-Oncology Research and a Professor in the Departments of Radiology, Radiation Oncology, Pathology and Biomedical Engineering at Duke University.  He received his undergraduate degree in chemistry from Clark University (Worcester, MA) and his Ph.D. in chemistry from Washington University (St. Louis, MO).  He received his postdoctoral training at Argonne National laboratory in radiophamaceutical chemistry.  Prior to joining the faculty at Duke, he held academic positions at the University of Chicago, Dana-Farber Cancer Institute and Harvard Medical School.  The author of more than 370 scientific publications and patents, his primary research interest is in radiochemistry applied to cancer imaging and targeted radionuclide therapy.  His laboratory has been responsible for the development and validation of many of the most widely used methodologies for labeling antibodies, antibody fragments and peptides with radiohalogens including 18F, 131I and 211At.  A major focus of his research has been the development of targeted radiotherapeutics labeled with alpha particle emitters, including their production, labeling chemistry, radiation dosimetry and clinical translation.  Working with his clinical colleagues, he has played a major role in the design, performance and interpretation of multiple first-in-human molecular imaging and targeted radiotherapy trials. Dr. Zalutsky’s  honors and awards include the Berson-Yalow Award and the Aebersold Award from the Society of Nuclear Medicine for outstanding achievement in basic nuclear medicine science, and a MERIT Award from the National Cancer Institute for his research in developing novel radiochemistry for targeted radiotherapy and molecular imaging probe development and clinical translation.